Maggie L. Wong

Maggie Wong is a partner in Goodwin’s nationally recognized Life Sciences group. She represents private and public companies in the biotechnology, pharmaceutical, digital health and medical technology industries, serving as a legal and business adviser across their entire corporate lifecycle. Maggie provides strategic and legal advice to clients as they develop, in-license and acquire intellectual property and other assets, raise capital to fund their operations, execute on strategic alliances and engage in exit transactions. Maggie regularly counsels clients on pre-incorporation planning, seed, venture and late-stage private financings, IPOs and other capital markets transactions, SEC compliance, corporate governance, and mergers and acquisitions. She also has substantial experience advising on licensing, collaboration, partnering, distribution, and other commercial agreements.

Maggie is a member of Goodwin’s Partnership Committee and Opinions Committee. Maggie is also a member of Goodwin’s PropSci practice which is focused on supporting the intersection of real estate and life sciences through thoughtful collaboration across the two practice areas.

Private Company Financing Transactions

• Absci in its $125 million crossover financing and $65 million Series E Preferred Stock financing
• Alector Corporation in its $133 million Series E Preferred Stock financing
• Arch Oncology in its $50 million Series B financing
• BridgeBio Pharma in its $299.2 million Series D financing
• BridgeBio Pharma in its $65 million initial investment in and launch of QED Therapeutics
• CARGO Therapeutics in its $200 million Series A financing
• Eidos Therapeutics in its $64 million Series B Preferred Stock financing
• Global Blood Therapeutics in its $40.7 million Series A Preferred Stock financing and $48 million Series B Preferred Stock financing
• Human Immunology Biosciences, Inc. (HI-Bio) in its $95 million Series B Preferred Stock financing
• InterVenn Biosciences in its $201 million Series C Preferred Stock financing
• Graphite Bio in its $150 million Series B financing
• MyoKardia in its $46 million Series B Preferred Stock financing
• Redmile Group in multiple investments, including as lead investor in Shattuck Labs’ $118 million Series B financing, Annexon’s $100 million Series D financing, LAVA Therapeutics’ $83 million Series C financing and Mammoth Biosciences’ $150 million Series D financing
• TheRas Inc. (dba BridgeBio Oncology Therapeutics) in its $200 million preferred stock financing

Initial Public Offerings and Public Company Financing Transactions

• Absci in its $230 million initial public offering, establishment of a $100 million “at-the-market” offering facility and $86.4 million follow-on offering
• Biomea Fusion in its $172.5 million follow-on offering and establishment of a $100 million “at-the-market” offering facility
• BridgeBio Pharma in its $372 million initial public offering, $475 million and $748 million convertible senior note offerings, $150 million follow-on offering, $250 million PIPE, establishment of a $350 million “at-the-market” offering facility and $275 million follow-on offering
• Eidos Therapeutics in its $122 million initial public offering and establishment of a $100 million “at-the-market” offering facility
• Fate Therapeutics, Inc. in its initial public offering, subsequent private placement transactions, $171.3 million and $432 million follow-on public offerings and $100 million concurrent follow-on offering and private placement 
• Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million, $125 million, $100 million and $250 million follow-on public offerings and establishment of a $200 million “at-the-market” offering facility
• Graphite Bio in its $273.7 million initial public offering and establishment of a $75 million “at-the-market” offering facility
• MyoKardia in its $54 million initial public offering and subsequent $65 million, $134 million, $184 million, $271 million and $604 million follow-on public offerings
• The initial purchasers in MannKind Corporation’s $230 million convertible senior note offering
• Assembly Biosciences in its $60 million and $155 million follow-on public offerings and establishment of a $75 million “at the market” offering facility

M&A and Other Strategic Transactions

• HI-Bio in its definitive agreement with Biogen (Nasdaq: BIIB) to be acquired for $1.15 billion upfront and up to $650 million in potential milestones
• Harpoon Therapeutics in its sale to Merck for an approximate total equity value of $680 million
• Graphite Bio in its reverse merger with LENZ Therapeutics
• Global Blood Therapeutics in its $5.4 billion sale to Pfizer
• Senti Biosciences in its business combination with Dynamics Special Purpose Corporation to become a Nasdaq-listed company (SNTI)
• MyoKardia in its $13.1 billion sale to Bristol-Myers Squibb
• Absci in its acquisitions of Denovium, Inc. and Totient, Inc.
• Delinia in its sale to Celgene for $300 million upfront and $475 million in milestone payments
• F-star Alpha in its exclusive option agreement with Bristol-Myers Squibb for aggregate consideration of up to $475 million
• Spinifex Pharmaceuticals in its $200 million upfront sale to Novartis plus undisclosed clinical development and regulatory milestones
• BridgeBio Pharma and its affiliates Navire and QED in strategic collaboration agreements with LianBio for the development and commercialization of targeted oncology drug candidates in China
• BridgeBio Pharma in its agreement with Alexion Pharmaceuticals to acquire a synthetic enzyme co-factor therapy and its launch of Origin Biosciences to support the compound’s clinical development
• Artisan Pharma in its sale to Asahi Kasei Pharma for an undisclosed amount
• Assembly Pharmaceuticals in its merger with Ventrus Biosciences to become Assembly Biosciences, Inc. (NASDAQ: ASMB)
• Gallus Biopharmaceuticals in its acquisition from Centocor Biologics, a subsidiary of Johnson & Johnson, of an FDA-approved, commercially certified biologics manufacturing facility and its entry into an agreement for the commercial manufacture of Remicade and Stelara
• Alere in its acquisition from ACON Laboratories of ACON’s worldwide lateral flow immunoassay diagnostics business
• A major buyer of pharmaceutical royalties in the acquisition of a royalty interest from a private university for over $90 million

Maggie is a member of the American Bar Association and the San Francisco Bar Association.

Prior to joining Goodwin, Maggie was a corporate associate at Cooley LLP and Heller Ehrman LLP representing emerging companies. During law school, Maggie interned in the Office of the General Counsel of the U.S. Securities and Exchange Commission in Washington, D.C.

Maggie has been recognized by Chambers USA, The Legal 500 U.S. and LMG Life Sciences for her corporate and transactional work in the life science industry and was recognized by the Minority Corporate Counsel Association as a 2021 MCCA Rainmaker. In law school, Maggie was a Senior Articles Editor for the Asian Law Journal.

Maggie has presented on “Asset Spin-Outs: In-Licensing Products and Technology from Biopharma” to the Silicon Valley Association of General Counsel and “Crafting International Business Agreements for Calculated Growth and Sustainability” to various biotech and pharma executives at the American Conference Institute.